IP Library Granted Patent US 9,063,034
Granted Patent B1
US 9,063,034 · App. 13/654,222 · Granted Jun 23, 2015

Determination of the absence or presence of

Inventors: Dustin Nielsen (Poynette, WI); Rachel Wezeman (Middleton, WI); Matthew Bristol (Sun Prairie, WI); Mark Eifler (Madison, WI); Lisa Petersen (Lodi, WI); Erik Walke (Deforest, WI); Lin Rao (Madison, WI)
Assignee: Scientific Protein Laboratories, LLC
G01N1/00A61K2121/00C12Q2304/00G01N2333/994G01N2333/32G01N2333/195
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,063,034
App. No.
13/654,222
Granted
Jun 23, 2015
Kind
B1
Abstract

Disclosed is a method for the determination of the absence or presence of bacillus cereus enterotoxin in a protein sample via a western blot.

Claims (12)

1. A method for determining the absence or presence of one or more components of Bacillus Diarrheal Enterotoxin (BDE) in a pancreatin Active Pharmaceutical Ingredient (API) sample comprising separating the one or more components of BDE from the pancreatin API sample by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and identifying one or more components of BDE by using at least one probe antibody specific for at least one or more components of BDE; wherein the one or more components of BDE are selected from the group consisting of Hemolysin BL (Hbl), Nonhemolytic Enterotoxin (Nhe), Cytotoxin K (CytK) and Enterotoxin T (BcET).

2. The method according to claim 1 wherein identifying the one or more components further comprises

transferring the separated components to a nitrocellulose membrane and sequentially exposing the components to solutions containing primary antibodies, and

soaking the membrane in a substrate solution to develop a colored reaction of the bound primary antibody to the component, resulting in identifying the component as a visible band on the membrane.

3. The method according to claim 2 wherein the one or more components is Nhe.

4. The method according to claim 3 wherein the Nhe component is represented by a NheA subunit.

5. The method according to claim 1 wherein the ratio of sodium dodecyl sulfate to pancreatin sample in the SDS-PAGE is about 1.4 to 1.

6. The method according to claim 2 wherein the SDS-PAGE is run with a matrix positive control and a blank positive control to determine the detection of BDE.

7. The method according to claim 1 wherein the SDS-PAGE is run on a Bis-Tris or Tris-Glycine SDS-polyacrylamide gel.

8. The method according to claim 2 wherein the components are exposed to solutions containing secondary antibodies after exposure to the primary antibodies.

9. The method according to claim 6 wherein the membrane is stained to detect the primary antibody bound component.

10. The method according to claim 9 wherein the stain is selected from the group consisting of chloronapthol and diaminobenzidine, nitro-blue tetrazolium and 5-bromo-4-chloro-3′-indolphosphate.

Assignments (2)
SECURITY INTEREST Recorded Apr 3, 2018
From: SCIENTIFIC PROTEIN LABORATORIES LLC; NOVAHEALTH BIOSYSTEMS, LLC
To: BMO HARRIS BANK N.A.
Reel/Frame 045428/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2013
From: NIELSEN, DUSTIN; WEZEMAN, RACHEL; BRISTOL, MATTHEW; EIFLER, MARK; PETERSEN, LISA J.; WALKE, ERIK; RAO, LIN
To: SCIENTIFIC PROTEIN LABORATORIES, LLC
Reel/Frame 029790/0040 →
Continuity (1)
Provisional Application 61547999 · Oct 17, 2011